Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salipro SLC Oncology
- Development stage
- Preclinical
- Lead developer
- Salipro Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Salipro Biotech's SLC Oncology program is a preclinical drug discovery initiative focused on the Solute Carrier (SLC) transporter superfamily for the treatment of cancer. SLCs are multi-pass transmembrane proteins that facilitate the transport of essential nutrients and metabolites; their dysregulation is a hallmark of cancer metabolism. The program utilizes the proprietary Salipro® technology, which incorporates membrane proteins into stable lipid nanoparticles (Salipro® particles), maintaining their native conformation and functionality. This platform enables the identification and development of therapeutic modalities, including monoclonal antibodies and small molecules, against these historically difficult-to-drug targets. The program is distinct from Salipro's MCT1 (SLC16A1) program, which also targets a member of the SLC family.
- Other names
- Solute Carrier (SLC)Solute Carrier (SLC) Oncology program
02
Targets
CCL21 (Chemokine (C-C motif) ligand 21)
Beyond the preview
Go deeper on Salipro SLC Oncology.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salipro SLC Oncology.